At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 162 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Escitalopram 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Long-term Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
In Brief
A Phase 4 clinical trial evaluating Escitalopram for Major Depressive Disorder. Completed, enrolled 162 participants across 16 sites.
Detailed Summary
This study will evaluate the long-term safety and tolerability of escitalopram (Lexapro) in children 7 to 11 years of age with major depressive disorder (MDD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedSep 2010
Primary CompletionJan 2013
Study CompletionApr 2013
TodayJul 2026
First PostedSep 10, 2010
Enrollment StartSep 1, 2010
Primary CompletionJan 1, 2013
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.8 years ago
Interventions
Escitalopramdrug
Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.